Thyroid Nodules: Causes, Diagnosis, and When to Seek Treatment

What Exactly Is a Thyroid Nodule?

A thyroid nodule is a discrete, solid or fluid-filled growth that arises within the thyroid gland, a butterfly-shaped structure sitting at the base of the neck that produces thyroxine (T4) and triiodothyronine (T3). Most nodules cause no symptoms. The global prevalence when high-resolution ultrasound is used reaches 19-68% in unselected populations, compared with only 3-7% detectable by palpation alone, according to an analysis published in the Journal of the American Medical Association [1].

Thyroid hormones regulate basal metabolic rate, cardiac output, bone turnover, and cognitive function. When a nodule distorts hormone production, either hypo- or hyperthyroidism can result. Most nodules, however, are non-functional and do not alter TSH, free T4, or free T3 levels at all.

Nodules range from simple cysts filled with colloid to complex solid masses with calcification. Size alone does not predict cancer risk. A 4 cm benign colloid cyst carries far less concern than a 9 mm nodule with microcalcifications and an irregular margin, which is why ultrasound classification systems now drive the biopsy decision rather than diameter cutoffs.

What Causes Thyroid Nodules?

Several distinct processes produce nodules, and identifying the underlying mechanism changes management. Iodine deficiency remains the leading worldwide cause, driving colloid accumulation and follicular hyperplasia; the World Health Organization estimates that 1.88 billion people live in iodine-insufficient regions [2]. In iodine-replete countries such as the United States, the most common etiology shifts to Hashimoto's thyroiditis.

Hashimoto's Thyroiditis. This autoimmune condition targets thyroid peroxidase (TPO) and thyroglobulin with specific IgG antibodies, producing lymphocytic infiltration and, eventually, fibrosis. The inflamed gland often develops multiple small nodules or a diffusely heterogeneous texture on ultrasound. Hashimoto's is the leading cause of hypothyroidism in the developed world, affecting roughly 5 in 100 people and showing a 7:1 female-to-male predominance [3]. Patients typically present with fatigue, cold intolerance, constipation, and unexplained weight gain as TSH climbs above the reference range of 0.4-4.0 mIU/L.

Graves' Disease. The immune system generates thyroid-stimulating immunoglobulins (TSI) that bind the TSH receptor and continuously activate hormone synthesis. The result is hyperthyroidism: weight loss despite normal or increased appetite, heat intolerance, tremor, palpitations, and the characteristic finding of diffuse goiter. Graves' disease accounts for approximately 60-80% of all hyperthyroidism cases in iodine-replete countries [4]. A toxic nodule or toxic multinodular goiter is a separate entity in which one or more autonomously functioning nodules produce excess T3 and T4 independent of TSH signaling.

Other etiologies include simple colloid cysts, follicular adenomas, acute or subacute thyroiditis, and, in a minority of cases, primary thyroid malignancy.

How Are Thyroid Nodules Classified and Scored?

The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) assigns points for five ultrasound feature categories: composition (solid, mixed, cystic), echogenicity, shape (taller-than-wide vs. wider-than-tall), margin regularity, and echogenic foci (microcalcifications, comet-tail artifacts). Total points map to TR1 (benign) through TR5 (high suspicion), each with its own size threshold for fine-needle aspiration (FNA) biopsy [5].

| TI-RADS Level | Point Range | FNA Threshold | |---|---|---| | TR1 (benign) | 0 | No biopsy | | TR2 (not suspicious) | 2 | No biopsy | | TR3 (mildly suspicious) | 3 | ≥2.5 cm | | TR4 (moderately suspicious) | 4-6 | ≥1.5 cm | | TR5 (highly suspicious) | ≥7 | ≥1 cm |

A validation study of 2,000 nodules found that ACR TI-RADS reduced unnecessary biopsies by 37.8% compared with prior ATA guidelines while maintaining high sensitivity for detecting malignancy [5].

The Role of TSH Before Biopsy

Every nodule evaluation should start with serum TSH. A suppressed TSH (below approximately 0.4 mIU/L) suggests the nodule may be autonomously producing hormones. In that scenario, the 2016 American Thyroid Association (ATA) guidelines recommend a radionuclide scan (technetium-99m or I-123 scintigraphy) before FNA, because a "hot" (autonomously functioning) nodule has a malignancy risk of only about 1% and biopsy can generally be deferred [6]. A normal or elevated TSH does not trigger scintigraphy as the first step.

"For patients with a serum TSH below the lower limit of the normal reference range, a radionuclide thyroid scan should be performed as the initial diagnostic evaluation." That language appears verbatim in the ATA's 2016 guideline on the management of thyroid nodules and differentiated thyroid cancer [6].

Subclinical Hypothyroidism and Its Relationship to Nodules

Subclinical hypothyroidism, defined as a TSH between 4.5 and 10 mIU/L with a normal free T4, affects an estimated 3-8% of the general population and up to 20% of women over age 60 [7]. Many patients with Hashimoto's thyroiditis pass through this biochemical state before progressing to overt hypothyroidism.

Whether to treat subclinical hypothyroidism with levothyroxine remains contested. The TRUST trial (N=737 adults aged 65 years or older) found no difference in thyroid-related symptoms, fatigue scores, or quality-of-life measures between levothyroxine and placebo after 12 months of follow-up, published in JAMA Internal Medicine in 2017 [8]. Conversely, patients younger than 65 with TSH persistently above 7-10 mIU/L, positive anti-TPO antibodies, or symptoms consistent with hypothyroidism are generally candidates for a trial of therapy under current American Association of Clinical Endocrinology (AACE) guidance [9].

Subclinical hypothyroidism does not independently cause nodules, but the two conditions frequently coexist in Hashimoto's thyroiditis, where the inflamed gland produces both elevated TSH and nodular or heterogeneous texture.

Fine-Needle Aspiration: What to Expect

FNA biopsy is a brief office procedure. Under ultrasound guidance, a 25- or 27-gauge needle is passed into the nodule two to four times to collect material for cytological analysis. The Bethesda System for Reporting Thyroid Cytopathology provides six categories that link cytology result to an estimated malignancy risk [10]:

1. Bethesda I (non-diagnostic): 5-10% malignancy risk; repeat FNA recommended
2. Bethesda II (benign): 0-3% malignancy risk; surveillance ultrasound
3. Bethesda III (atypia of undetermined significance): 10-30% risk; molecular testing or repeat biopsy
4. Bethesda IV (follicular neoplasm): 25-40% risk; molecular testing or diagnostic lobectomy
5. Bethesda V (suspicious for malignancy): 50-75% risk; near-total thyroidectomy or lobectomy
6. Bethesda VI (malignant): 97-99% risk; surgical resection

Molecular panels such as the Afirma Gene Sequence Classifier or ThyroSeq v3 are now standard for Bethesda III and IV nodules, reducing unnecessary diagnostic surgeries by reclassifying a substantial proportion of indeterminate results as benign. A 2019 multicenter study in JAMA Oncology reported that ThyroSeq v3 achieved a negative predictive value of 97% in Bethesda III nodules [11].

Thyroid Cancer Risk: Who Is Most Vulnerable?

Roughly 43,720 new thyroid cancer cases are diagnosed in the United States each year according to the National Cancer Institute, with papillary thyroid carcinoma (PTC) accounting for approximately 85% of cases [12]. Despite its frequency, PTC carries a 10-year disease-specific survival rate above 98% for localized disease.

Risk factors for malignancy within a discovered nodule include:

• History of head or neck radiation, especially during childhood
• Family history of medullary thyroid cancer or MEN2 syndrome
• Age <20 or age over 70 at discovery
• Male sex (nodules are more common in women, but are more likely malignant in men)
• Rapid nodule growth or new-onset hoarseness suggesting recurrent laryngeal nerve involvement
• Cervical lymphadenopathy on ultrasound

Serum calcitonin, while not universally recommended in the United States, identifies medullary thyroid carcinoma, which arises from parafollicular C cells and carries a different prognosis than PTC. The European Thyroid Association recommends routine calcitonin measurement in nodule evaluation [13].

Active Surveillance: An Option for Low-Risk Papillary Microcarcinomas

Not every thyroid cancer requires immediate surgery. Japanese protocols pioneered active surveillance for papillary thyroid microcarcinoma (PTMC), defined as PTC measuring <1 cm. The Kuma Hospital cohort in Kobe followed 1,235 patients with low-risk PTMC under active surveillance for a median of 75 months. Disease progression (10% size increase or new nodal disease) occurred in only 8.0% of patients at 10 years, and no surveillance patient died of thyroid cancer during follow-up [14].

The HealthRX clinical team stratifies PTMC surveillance candidates using four criteria: nodule diameter <9 mm, no evidence of extrathyroidal extension on ultrasound, no central or lateral neck nodal metastases, and no BRAF V600E mutation identified on molecular testing. Patients meeting all four can reasonably discuss observation with a 6-month initial follow-up ultrasound before committing to the operating room.

Treatment Options Beyond Watchful Waiting

When intervention is indicated, the choice depends on nodule type, size, functional status, and patient preference.

Levothyroxine. For overt hypothyroidism from Hashimoto's thyroiditis, levothyroxine (synthetic T4) is the standard of care at an average full-replacement dose of 1.6 mcg/kg/day, titrated to a TSH within the reference range [9]. Some patients with persistent fatigue on levothyroxine monotherapy report subjective improvement with the addition of low-dose liothyronine (T3), though the ATA's 2014 guidelines note that evidence from randomized controlled trials remains mixed [15].

Antithyroid Drugs. Methimazole at 10-30 mg/day is the first-line medical therapy for Graves' disease in the United States, normalizing thyroid hormone levels in 6-8 weeks in most patients. Propylthiouracil (PTU) is preferred during the first trimester of pregnancy because methimazole carries a small risk of aplasia cutis in the fetus [4].

Radioactive Iodine (RAI). I-131 ablation is a definitive treatment for both Graves' disease and toxic nodular goiter. A single oral dose selectively destroys overactive thyroid tissue. The majority of patients become hypothyroid after RAI and require lifelong levothyroxine.

Surgery. Total thyroidectomy or lobectomy addresses large compressive goiters, confirmed or highly suspected malignancy, and nodules that are cosmetically or functionally problematic. Post-thyroidectomy patients with differentiated thyroid cancer may need RAI adjuvant therapy and TSH-suppression doses of levothyroxine based on their ATA risk category.

Thermal Ablation. Radiofrequency ablation (RFA) is a minimally invasive alternative for benign symptomatic nodules in patients who decline surgery. A systematic review of 1,459 nodules treated with RFA reported a mean volume reduction of 79.7% at 12 months without major complications in most centers [16]. RFA is not standard for malignant nodules outside clinical trial settings.

Monitoring Benign Nodules Over Time

Bethesda II (benign) nodules on FNA do not require repeat biopsy unless ultrasound features worsen or significant growth occurs. The ATA defines significant growth as a 20% increase in at least two nodule dimensions plus a minimum 2 mm increase in each of those dimensions. Under that definition:

• Low-suspicion nodules: repeat ultrasound in 12-24 months; if stable, extend interval
• Intermediate-suspicion nodules: repeat ultrasound in 12-18 months
• High-suspicion nodules: repeat ultrasound in 6-12 months after initial benign biopsy

Patients with Hashimoto's thyroiditis should have TSH checked at least annually because overt hypothyroidism can develop at any time, even when levels were normal the year prior. Anti-TPO antibody titers do not need to be repeated once the diagnosis is established, as they do not guide therapy adjustments.

Thyroid Nodules During Pregnancy

Pregnancy is not a reason to delay evaluation of a thyroid nodule. TSH reference ranges shift in the first trimester to approximately 0.1-2.5 mIU/L because hCG weakly stimulates the TSH receptor, making biochemical interpretation different from non-pregnant standards. The American Thyroid Association's 2017 guidelines on thyroid disease in pregnancy state that FNA biopsy is safe in all trimesters and should not be postponed solely because of gestational status [17].

Overt hypothyroidism in pregnancy is clearly associated with increased risk of miscarriage, preterm birth, and impaired fetal neurodevelopment. The goal TSH in a levothyroxine-treated pregnant patient is below 2.5 mIU/L in the first trimester. Levothyroxine dose typically needs to increase by 20-30% in the first 4-8 weeks of pregnancy, so early TSH retesting is essential after conception is confirmed.

Practical Steps After a Nodule Is Found

When a nodule is discovered incidentally on a CT, MRI, or PET scan, the appropriate next step is a dedicated thyroid ultrasound by a sonographer experienced in thyroid imaging, not immediate biopsy. The radiologist's report should include ACR TI-RADS scoring, and the ordering clinician should obtain serum TSH simultaneously.

From there, the ACR TI-RADS score combined with TSH result and clinical risk factors determines the path: observe, biopsy, or scan. A clinical endocrinologist should be involved if TSH is suppressed, if the nodule is TI-RADS 4 or higher, or if the patient has any of the high-risk features listed earlier.

Patients identified through a telehealth endocrinology visit should receive a referral for in-person ultrasound-guided FNA if biopsy criteria are met, since remote physical examination alone cannot exclude neck mass with sufficient reliability.

The ACR published its most recent ACR TI-RADS white paper in Radiology in 2017, with the authors writing: "Use of ACR TI-RADS should decrease the number of thyroid nodule biopsies while maintaining acceptable rates of detecting malignancy" [5]. Following that guidance, a TSH result above 10 mIU/L in a patient with a TR4 nodule warrants both endocrinology referral and FNA scheduling within 4-6 weeks.